Product Information
Registration Status: ActiveSIN13616P
JURNISTA PROLONGED RELEASE TABLET 8MG is approved to be sold in Singapore with effective from 2009-03-18. It is marketed by JOHNSON & JOHNSON PTE LTD, with the registration number of SIN13616P.
This product contains Hydromorphone 8.72mg in the form of TABLET, EXTENDED-RELEASE. It is approved for ORAL use.
This product is manufactured by Alza Corporation in UNITED STATES.
It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.
Product Reference
Important Note: For generic product, the SPC/PIL provided may not be brand specific.
{{/items}} {{^items}}Description
An opioid analgesic derived from morphine and used mainly as an analgesic. It has a shorter duration of action and is more potent than morphine. [PubChem]
Indication
For the relief of moderate to severe pain such as that due to surgery, cancer, trauma/injury, or burns.
Mechanism of Action
Hydromorphone is a narcotic analgesic; its principal therapeutic effect is relief of pain. Hydromorphone interacts predominantly with the opioid mu-receptors. These mu-binding sites are discretely distributed in the human brain, with high densities in the posterior amygdala, hypothalamus, thalamus, nucleus caudatus, putamen, and certain cortical areas. They are also found on the terminal axons of primary afferents within laminae I and II (substantia gelatinosa) of the spinal cord and in the spinal nucleus of the trigeminal nerve. In clinical settings, Hydromorphone exerts its principal pharmacological effect on the central nervous system and gastrointestinal tract. Hydromorphone also binds with kappa-receptors which are thought to mediate spinal analgesia, miosis and sedation.
Pharmacokinetics
- Absorption
- Better absorbed orally than morphine
- Distribution
- Metabolism
- Primarily hepatic. After absorption hydromorphone is metabolized by the liver to the glucuronide conjugate which is then excreted in the urine. Hydromorphone is metabolized to the major metabolites hydromorphone-3-glucuronide, hydromorphone-3-glucoside and dihydroisomorphine-6-glucuronide.
- Elimination
Clearance
* 1.96 L/min
Toxicity
Hydromorphone is a schedule II narcotic which can lead to physical dependence or addiction. High doses lead to respiratory depression, nausea, and vomiting. Overdoses lead to extreme somnolence progressing to stupor or coma, skeletal muscle flaccidity, cold and clammy skin, and sometimes bradycardia and hypotension. In severe overdosage, apnea, circulatory collapse, cardiac arrest and death may occur.
Active Ingredient/Synonyms
(-)-(5R)-4,5-Epoxy-3-hydroxy-9alpha-methylmorphinan-6-one | 4,5-Epoxy-3-hydroxy-17-methylmorphinan-6-one | 4,5alpha-Epoxy-3-hydroxy-17-methyl-6-morphinanone | 6-Deoxy-7,8-dihydro-6-oxomorphine | 7,8-Dihydromorphinone | Dihydromorfinon | Dihydromorphinone | Dimorphone | Hidromorfona | Hydromorfona | Hydromorphone | Hydromorphonum | Idromorfone | Hydromorphone |
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.